January 18, 2024 11:03 AM EST
News Briefing

Virid­i­an’s $150M of­fer­ing; Sur­rozen scraps IBD drug can­di­date; As­sem­bly ends deal with In­di­ana Uni­ver­si­ty

Katherine Lewin

News Reporter

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

Plus, news about Vor Bio, Vaxxin­i­ty, Im­mat­ics and Cer­tis On­col­o­gy:

Virid­i­an Ther­a­peu­tics’ $150M pub­lic of­fer­ing: The Waltham, MA-based biotech is sell­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times